Zacks Research Has Bearish Estimate for IQVIA Q1 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at Zacks Research reduced their Q1 2025 earnings estimates for IQVIA in a research report issued on Thursday, November 21st. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.34 per share for the quarter, down from their prior forecast of $2.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Zacks Research also issued estimates for IQVIA’s Q2 2025 earnings at $2.59 EPS and FY2025 earnings at $10.58 EPS.

Several other analysts have also commented on the stock. Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Down 1.4 %

Shares of IQVIA stock opened at $201.24 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The firm has a market capitalization of $36.53 billion, a PE ratio of 26.41, a P/E/G ratio of 2.08 and a beta of 1.51. The firm’s 50-day moving average price is $221.18 and its 200 day moving average price is $226.75.

Institutional Trading of IQVIA

Several large investors have recently bought and sold shares of IQV. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the second quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp acquired a new position in IQVIA in the 3rd quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the 2nd quarter worth $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.